A major investment project in the pharmaceutical sector has been implemented in the Novosibirsk region. The local company Renewal (PFC “Obnovlenie”) has commissioned a new line for the production of medicines in glass ampoules. This was announced to journalists on Thursday, February 19, by the acting Minister of Industry, Trade and Entrepreneurship Development of the region, Denis Ryaguzov.
Project Scale
The new launch is only part of the company’s global program to expand its production capacity.
“The company continues to implement investment projects worth 4 billion rubles, which include the construction of three new buildings and the production of 17 new drugs.”
— Denis Ryaguzov, Acting Minister of Industry, Trade and Entrepreneurship Development of the Novosibirsk Region
The expected production volume on the new line will be about 14.5 million packages of ampoule medicines per year.
Focus on Import Substitution
The implementation of this project is of strategic importance for ensuring drug security. As part of the operation of the new workshops (the deployment of which is expected to be completed by 2027), the company is aimed at import substitution of a whole range of highly demanded drugs. Among them:
- Diclofenac;
- Ketorolac;
- Ketoprofen;
- Drotaverine;
- Pyridoxine.
As noted in the regional government, such large-scale investments allow the enterprise to introduce the most modern equipment and advanced technologies. Ultimately, this leads to an increase in labor productivity, a decrease in production costs, and a rise in the quality of medical care for the population.
Manufacturer Profile
PFC “Obnovlenie” (operating under the Renewal brand) is one of the key players in the Russian pharmaceutical market. The main production facilities of the company are located directly in Novosibirsk and in the Suzunsky district of the Novosibirsk region.
The enterprise specializes in the production of a wide range of medicines in various forms. In addition to the new ampoule injection solutions, Renewal’s assortment includes solid forms (tablets, capsules, powders), as well as liquid forms (eye and nasal drops). According to analytical systems, the company demonstrates stable financial results: for instance, the enterprise’s revenue reached 9 billion rubles back in 2021, with a net profit of about 1.4 billion rubles.
